FDA Manufacturing-Change Reviews Will Shift From Compliance Office To ODE
This article was originally published in The Gray Sheet
Executive Summary
The move is in line with the agency’s intention to focus on the total product life-cycle, such that the same staffers that review an original marketing submission will look at the safety and effectiveness of manufacturing changes.